Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 48.59%.

  • United Therapeutics' EBITDA Margin rose 27800.0% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 29200.0%. This contributed to the annual value of 47.86% for FY2024, which is 30500.0% down from last year.
  • As of Q3 2025, United Therapeutics' EBITDA Margin stood at 48.59%, which was up 27800.0% from 45.64% recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' EBITDA Margin ranged from a high of 26010.0% in Q4 2023 and a low of 4527.85% during Q4 2024
  • In the last 5 years, United Therapeutics' EBITDA Margin had a median value of 48.59% in 2025 and averaged 1171.43%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 259742700bps in 2023, then tumbled by -305378500bps in 2024.
  • Over the past 5 years, United Therapeutics' EBITDA Margin (Quarter) stood at 40.9% in 2021, then decreased by -13bps to 35.73% in 2022, then soared by 72701bps to 26010.0% in 2023, then tumbled by -117bps to 4527.85% in 2024, then surged by 101bps to 48.59% in 2025.
  • Its EBITDA Margin stands at 48.59% for Q3 2025, versus 45.64% for Q2 2025 and 48.19% for Q1 2025.